

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form SC 13G

BIOMARIN PHARMACEUTICAL INC
Form SC 13G
August 05, 2004

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G
Under the Securities Exchange Act of 1934

Biomarin Pharmaceutical Inc.
(Name of Issuer)

Common Stock
(Title of Class of Securities)

09061G101
(CUSIP Number)

June 1, 2004

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☒ Rule 13d-1(b)

☐ Rule 13d-1(c)

☐ Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 09061G101

1. Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).

OrbiMed Advisors LLC

2. Check the Appropriate Box if a Member Of a Group (See Instructions)

☐ (a)

☐ (b)

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form SC 13G

3. SEC Use Only
4. Citizenship or Place of Organization
Delaware
5. Sole Voting Power: 0 Number of
Number of
Shares
Beneficially
Owned by
Each Reporting
Person With
6. Shared Voting Power: 2,538,900
7. Sole Dispositive Power: 0
8. Shared Dispositive Power: 2,538,900
9. Aggregate Amount Beneficially Owned by Each Reporting Person
2,538,900
10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares
(See Instructions)
11. Percent of Class Represented by Amount in Row (9) 3.94%
12. Type of Reporting Person (See Instructions) IA

CUSIP No. 09061G101

1. Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).

OrbiMed Capital LLC
2. Check the Appropriate Box if a Member of a Group (See
Instructions)

☐ (a)
☐ (b)
3. SEC Use Only
4. Citizenship or Place of Organization
Delaware
5. Sole Voting Power: 0
Number of
Shares
Beneficially
Owned by
Each Reporting
Person With
6. Shared Voting Power: 693,300
7. Sole Dispositive Power: 0
8. Shared Dispositive Power: 693,300
9. Aggregate Amount Beneficially Owned by Each Reporting Person
693,300

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form SC 13G

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
11. Percent of Class Represented by Amount in Row (9) 1.08%
12. Type of Reporting Person (See Instructions) IA

CUSIP No. 09061G101

1. Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).

Samuel D. Isaly

2. Check the Appropriate Box if a Member of a Group (See Instructions)

☐ (a)

☐ (b)

3. SEC Use Only
4. Citizenship or Place of Organization

United States

5. Sole Voting Power: 0

Number of
Shares
Beneficially
Owned by
Each Reporting
Person With

6. Shared Voting Power: 3,232,200

7. Sole Dispositive Power: 0

8. Shared Dispositive Power: 3,232,200

9. Aggregate Amount Beneficially Owned by Each Reporting Person:
3,232,200
10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
11. Percent of Class Represented by Amount in Row (9) 5.02%
12. Type of Reporting Person (See Instructions) HC

Item 1. (a) Issuer: Biomarin Pharmaceutical Inc.

1. Address:
371 Bel Marin Keys Boulevard, Suite 210
Novato, California 94949

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form SC 13G

Item 2. (a) Name of Person Filing:

OrbiMed Advisors LLC
OrbiMed Capital LLC
Samuel D. Isaly

(b) Address of Principal Business Offices:

767 Third Avenue, 30th Floor
New York, New York 10017

(c) Citizenship:

Please refer to Item 4 on each cover sheet for each filing person

(d) Title of Class of Securities

Common stock

(e) CUSIP Number: 09061G101

Item 3. OrbiMed Advisors LLC and OrbiMed Capital LLC are investment advisors in accordance with ss.240.13d-1(b)(1)(ii)(E). Samuel D. Isaly is a control person in accordance with ss.240.13d-1(b)(1)(ii)(G).

Item 4. Ownership

Please see Items 5 - 9 and 11 for each cover sheet for each filing separately

Item 5. Ownership of Five Percent or Less of a Class

Not Applicable

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Reporting persons are holding 5.02% (3.94% in the case of OrbiMed Advisors LLC and 1.08% in the case of OrbiMed Capital LLC) of the securities on behalf of other persons who have the right to receive or the power to direct the receipt of dividends from, or proceeds from sale of, such securities. No one such other person's interest in the securities whose ownership is reported here relates to more than five percent of the class.

OrbiMed Advisors LLC and OrbiMed Capital LLC hold shares on behalf of Caduceus Capital Trust (765,000 shares), Caduceus Capital II, L.P. (443,400 shares), UBS Eucalyptus Fund, Ltd. (781,000 shares), PaineWebber Eucalyptus Fund, Ltd. (97,000 shares), HFR SHC Aggressive Fund (110,000 shares), Knightsbridge Post Venture IV L.P. (103,000 shares), Knightsbridge Integrated Holdings, V, LP (83,000 shares), Knightsbridge Netherlands II, L.P. (28,300 shares), Knightsbridge Integrated Holdings IV Post Venture, LP (48,400 shares), Knightsbridge Post Venture III, LP (46,700 shares), Knightsbridge Netherlands I LP (35,900 shares), Knightsbridge Netherlands III LP (16,700 shares), Knightsbridge Integrated Holdings II Limited (53,000 shares), Knightsbridge Venture Capital IV, L.P. (19,800 shares), Knightsbridge Venture Capital III LP (15,400), Finsbury Worldwide Pharmaceutical Trust (565,000 shares), Topanga XIII Inc. (18,300 shares) and, Caduceus Capital III, L.P. (2,300 shares).

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form SC 13G

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

Not Applicable

Item 8. Identification and Classification of Members of the Group

Not Applicable

Item 9. Notice of Dissolution of Group

Not Applicable

Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: August 3, 2004

OrbiMed Advisors LLC

By: /s/ Samuel D. Isaly

Name: Samuel D. Isaly

Title: President

OrbiMed Capital LLC

By: /s/ Samuel D. Isaly

Name: Samuel D. Isaly

Title: Managing Member

By: /s/ Samuel D. Isaly

Name: Samuel D. Isaly